In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

about

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

Item

http://www.wikidata.org/entity/Q50627316

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@en

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@nl

type

Item

label

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@en

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@nl

prefLabel

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@en

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.

@nl

P1476

In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors

@en

P2093

Gülru Kayık

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design

Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5

Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

Development and validation of a genetic algorithm for flexible docking

Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives

Phosphodiesterases in the CNS: targets for drug development

P304

2830-2852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07391102.2016.1231634

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Serdar Durdagi

Nurcan S Tuzun

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27581752

http://www.w3.org/2001/XMLSchema#string